Project Grant R01CA286064

Award Date 6/7/24
Completion Date 5/31/28
Dollars Obligated $2M
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02118, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $415,257 to the University of Virginia to conduct research aimed at identifying epigenetic and transcriptomic drivers of racial disparities in colorectal cancer risk and site-specific tumor development. The key products and services to be delivered under this 2-year award include: Identifying site-specific DNA methylation-associated gene expression signatures across different...
This Project Grant award from the National Institute on Minority Health and Health Disparities (CFDA 93.307 - Minority Health and Health Disparities Research) provides $1,738,400 to The University of Texas Southwestern Medical Center to conduct research on early-onset colorectal cancer (EOCRC) among a cohort of younger, underserved minority patients in the Dallas County safety-net healthcare system. The key objectives are to: 1) Describe the symptom burden and healthcare interactions leading...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $192,610 to The University of Kentucky Research Foundation and its sub-awardee Augusta University Research Institute to conduct a study entitled "Pathways to Prevention: Exploring Social Determinants of Health in Early Onset Colorectal Cancer." The primary objective is to evaluate the impact of various social determinants of health (SDOH) factors on early-onset...
This federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) provides $456,764 to the University of Chicago to study differences in bile acid metabolism and colonic responses between African Americans and non-Hispanic whites, and their potential connection to colorectal cancer disparities. The key objectives of this 2-year research project are to: 1) compare serum bile acid composition between the two populations, 2) perform...
This $215,546 Project Grant was awarded by the National Institute on Minority Health and Health Disparities (NIMHD), part of the National Institutes of Health (NIH), under the Minority Health and Health Disparities Research (CFDA 93.307) program. The project aims to evaluate the equity impact and cost-effectiveness of three real-world lung cancer screening strategies: the U.S. Preventive Services Task Force (USPSTF) guidelines, the American Cancer Society (ACS) guidelines, and a screening...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $714,062 to The Regents of the University of California, San Francisco to investigate the biological mechanisms contributing to racial disparities in outcomes for head and neck cancer, particularly oral squamous cell carcinoma, in Black patient populations. The research aims to: 1) Develop a prognostic model using gene expression signatures to predict disease progression risk in...
This $399,187 federal Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Virginia Commonwealth University to study the role of ATG16L1 isoforms in colorectal cancer health disparities. The key objectives are to: 1) Determine whether the ATG16L1 T300T isoform, which is more predominant in African Americans, promotes more aggressive colorectal tumor growth and metastasis compared to the A300A isoform found more in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) provides $197,640 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to develop implementation strategies to initiate colorectal cancer (CRC) screening in previously unscreened individuals aged 45 to 54 at a predominantly Black community health center in Boston, Massachusetts. The key objectives are to: (1) identify system-level determinants of...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
This Project Grant award from the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research) provides $432,304 to The Trustees of Columbia University in the City of New York to develop novel data integration methods to enhance cancer risk predictions for underrepresented Black and Hispanic populations. The key products and services to be delivered include: A transfer learning method that integrates shared knowledge from external studies to leverage cross-study data while...

ADDRESSING RACIAL DISPARITIES IN COLORECTAL CANCER RISK PREDICTION - PROJECT SUMMARY WITH BLACK MEN AND WOMEN EXPERIENCING A DISPROPORTIONATELY HIGH BURDEN OF COLORECTAL CANCER (CRC), THERE IS A CRITICAL NEED FOR NEW IMPROVED RISK PREDICTION TOOLS TO IDENTIFY THOSE AT HIGHEST RISK TO UNDERGO SCREENING AT EARLIER AGES OR MORE FREQUENTLY AS NEEDED. BLACK ADULTS HAVE THE HIGHEST INCIDENCE AND MORTALITY RATES OF ANY RACIAL AND ETHNIC GROUP IN THE US FOR REASONS ONLY PARTLY UNDERSTOOD AND THEIR RISK FACTORS HAVE NOT BEEN WELL- STUDIED TO DATE. FURTHER, BLACK AMERICANS EXPERIENCE PERSISTENTLY HIGH RATES OF EARLY-ONSET CRC DIAGNOSED IN YOUNGER ADULTS AGED LESS THAN 50 YEARS. EARLY-ONSET CRC IS AN EMERGING PUBLIC HEALTH CONCERN DUE TO RISING INCIDENCE RATES, LEADING TO A RECENTLY REDUCED ROUTINE SCREENING AGE OF 45 YEARS IN THE US. ESTABLISHED RISK PREDICTION TOOLS SUCH AS THE NCI'S COLORECTAL CANCER RISK ASSESSMENT TOOL WERE DEVELOPED AND VALIDATED ON WHITE POPULATIONS AND HAVE BEEN SHOWN TO PERFORM POORLY IN BLACK WOMEN AND HAVE NOT YET BEEN TESTED IN BLACK MEN. IN THIS GRANT OUR OVERARCHING GOAL IS TO DEVELOP NEW PERSONALIZED CRC RISK TOOLS WITH IMPROVED ACCURACY THAT ARE UNIQUELY TAILORED FOR BLACK AMERICANS, AND ARE BUILT AND VALIDATED ON THE DATA OF BLACK MEN AND WOMEN. OUR NEW WEB-BASED RISK MODELS WILL BE DEVELOPED USING THE RICH LONGITUDINAL DATA OF LARGE PROSPECTIVE ESTABLISHED US COHORTS OF BLACK ADULTS IN THE SOUTHERN COMMUNITY COHORT STUDY AND MULTIETHNIC COHORT STUDY WITH EXTERNAL VALIDATION IN THREE FURTHER COHORTS OF BLACK ADULTS. OUR THREE AIMS ARE: (A) TO DEVELOP AND EXTERNALLY VALIDATE NEW RISK PREDICTION MODELS FOR COLORECTAL CANCER IN BLACK MEN AND WOMEN BASED UPON EASILY OBTAINABLE LIFESTYLE, DEMOGRAPHIC, SOCIAL AND SCREENING FACTORS; (B) TO BUILD DYNAMIC RISK MODELS FOR CRC FOR BLACK ADULTS USING MODERN STATISTICAL AND MACHINE-LEARNING METHODS TO OBTAIN OPTIMAL PREDICTION PERFORMANCE, AND (C) TO DETERMINE IF ACCOUNTING FOR THE SITE OF THE COLORECTAL CANCER TUMOR IMPROVES THE INDIVIDUALIZED PREDICTION ACCURACY OF OUR NEW RISK MODELS IN BLACK ADULTS. DUE TO THE HIGH CRC INCIDENCE AND DEATH RATES IN BLACK ADULTS, OUR NEW RISK PREDICTION MODELS WILL HAVE SIGNIFICANT AND FAR-REACHING IMPLICATIONS FOR COLORECTAL CANCER SCREENING AND MORTALITY IN THE BLACK COMMUNITY. OUR NEW CLINICAL RISK TOOLS WILL PROVIDE ACCURATE PERSONALIZED RISK ASSESSMENTS OF CRC WHICH CAN BE USED BY BLACK ADULTS AND THEIR PHYSICIANS TO IDENTIFY THOSE AT HIGH RISK AND TO TARGET OPTIMAL, TIMELY AND EFFECTIVE CRC SCREENING AND LIFESTYLE PREVENTION STRATEGIES, LEADING TO EARLIER DETECTION OF CRC, REMOVAL OF PRECANCEROUS POLYPS DURING COLONOSCOPY AND REDUCED MORTALITY. OUR PROPOSED WORK CLOSELY ALIGNS WITH CURRENT KEY INITIATIVES OF NCI TO SUPPORT RESEARCH ON IMPROVING HEALTH EQUITY IN CANCER.

Posted 6/7/24, 12:00 AM